Featured Research

from universities, journals, and other organizations

Pepper Compound Could Aid Millions With Vitiligo

Date:
April 15, 2008
Source:
Oregon Health & Science University
Summary:
A family of compounds derived from black pepper extract have shown potential in animal studies to be effective in treating vitiligo, a skin pigmentation disorder. Vitiligo, which afflicts an estimated 100 million people worldwide, is characterized by the loss of pigment in affected areas of skin.

Oregon Health & Science University has licensed a family of compounds derived from black pepper extract – on which it owns the patents – to AdPharma, Inc. for potential pharmaceutical development. The compounds have shown potential in animal studies to be effective in treating vitiligo, a skin pigmentation disorder.

Related Articles


Vitiligo, which afflicts an estimated 100 million people worldwide, is characterized by the loss of pigment in affected areas of skin. It is the disease pop star Michael Jackson has publicly disclosed that he has. It is neither life-threatening nor contagious. But the sometimes unsightly white patches it causes produce emotional distress for many and often lead to social ostracism because of a widespread misperception that the condition is infectious.

An estimated 1 percent to 2 percent of the world’s population suffers from the malady. Current treatments, which rely on immunosuppression or ultraviolet radiation to stimulate repigmentation, are only partially effective, often producing a mottled appearance. Excessive ultraviolet (UV) radiation also poses the risk of skin cancer.

“Based on the animal studies we have done, these compounds, if proved safe in humans, promise far superior results in the treatment of vitiligo than current approaches,” said Amala Soumyanath, Ph.D., an associate professor of neurology, OHSU School of Medicine. “Vitiligo is a highly visible disease that can greatly affect patients psychologically and emotionally, even driving some to consider suicide. Any breakthrough in treating it would benefit a huge number of people around the world.”

Soumyanath and her collaborators reported on the effects of their compounds in animals in a paper just published in the British Journal of Dermatology. But development of the concept dates back more than a decade. Soumyanath discovered – in research on vitiligo that she initiated at King’s College London – that piperine, the alkaloid in black pepper responsible for its pungency, stimulated the proliferation of melanocytes in cell cultures. Melanocytes are the cells that produce pigmentation in the skin. The researchers then designed and tested many synthetic piperine analogs and identified a number that produced the same result.

The group subsequently found that piperine and two of its analogs – tetrahydropiperine (THP) and a cyclohexyl derivative (RCHP) produced light, even pigmentation when applied to the skin of a poorly pigmented mouse model. When combined with UV radiation, the skin grew significantly darker and showed none of the patchiness caused by UV treatment alone. Moreover, skin pre-treated with a piperine compound required fewer UV exposures, thus lowering the cancer risk, and it took longer for the pigmentation to fade again than when UV alone was used.

Since coming to OHSU in 2002, Soumyanath has established new collaborations with scientific and clinical researchers to continue work on this project. “Dr. Soumyanath’s recent discoveries open up completely new and exciting treatment possibilities for those individuals affected by vitiligo,” said Andrew Blauvelt, M.D., professor of dermatology at OHSU and one of Soumyanath’s recent collaborators. “There is a huge unmet need for this disease because we have very few treatments to offer patients right now,” he noted.

OHSU acquired the patents to Soumyanath’s piperine compounds from King’s College London and BTG International Ltd. in 2006 and succeeded in finding a commercial partner, AdPharma, to advance the compounds through pharmaceutical development. Soumyanath has a financial interest in AdPharma. This potential conflict has been disclosed to the OHSU Conflict of Interest in Research committee for management.

AdPharma, a diverse pharmaceutical company headquartered in Arlington Heights, Ill., licenses promising compounds from scientists, universities and biotech companies and advances them through the clinical testing stage. “Our key strength is being able to identify, through our computer models and past experience, promising drugs which we can then drive through our strong development structure,” said Anil Sunkara, the company’s chief executive officer.

The next step before clinical trials can be undertaken, said Soumyanath, is to determine in animal models whether the repigmentation effects of piperine compounds is associated in any way with melanoma or other skin cancers. “From our mouse studies so far, it doesn’t appear that is the case,” she said, “and we are hopeful that more detailed research will bear this out. OHSU has ideal facilities and expertise for further preclinical and clinical studies, and we are excited to have the support of AdPharma as we move toward testing these compounds in human vitiligo.”


Story Source:

The above story is based on materials provided by Oregon Health & Science University. Note: Materials may be edited for content and length.


Cite This Page:

Oregon Health & Science University. "Pepper Compound Could Aid Millions With Vitiligo." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080413172937.htm>.
Oregon Health & Science University. (2008, April 15). Pepper Compound Could Aid Millions With Vitiligo. ScienceDaily. Retrieved April 25, 2015 from www.sciencedaily.com/releases/2008/04/080413172937.htm
Oregon Health & Science University. "Pepper Compound Could Aid Millions With Vitiligo." ScienceDaily. www.sciencedaily.com/releases/2008/04/080413172937.htm (accessed April 25, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, April 25, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

85 Killed in Niger by Meningitis Since Start of Year

85 Killed in Niger by Meningitis Since Start of Year

AFP (Apr. 24, 2015) A meningitis outbreak in Niger has killed 85 people since the start of the year prompting authorities to close schools in the capital Niamey until Monday. Video provided by AFP
Powered by NewsLook.com
C-Section Births a Trend in Brazil

C-Section Births a Trend in Brazil

AFP (Apr. 24, 2015) More than half of Brazil&apos;s babies are born via cesarean section, as mothers and doctors opt for a faster and less painful experience despite the health risks. Duration: 02:02 Video provided by AFP
Powered by NewsLook.com
Anti-Malaria Jab Hope

Anti-Malaria Jab Hope

Reuters - News Video Online (Apr. 24, 2015) The world&apos;s first anti-malaria vaccine could get the go-ahead for use in Africa from October if approved by international regulators. Paul Chapman reports. Video provided by Reuters
Powered by NewsLook.com
3D Food Printing: The Meal of the Future?

3D Food Printing: The Meal of the Future?

AP (Apr. 23, 2015) Developers of 3D food printing hope the culinary technology will revolutionize the way we cook and eat. (April 23) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins